Evidence map›Paper›PMID 24270663›Full record

ArticleThe Journal of investigative dermatology2014

Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology.

Zoltan Pos, Tara L Spivey, Hui Liu, Michele Sommariva, Jinguo Chen, John R Wunderlich, Giulia Parisi, Sara Tomei, Ben D Ayotte, David F Stroncek and 7 more

Abstract read
In one paragraph

Article in The Journal of investigative dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Zoltan PosInfectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA; Hungarian Academy of Sciences-Semmelweis University "Lendület" Experimental and Translational Immunomics Research Group, Budapest, Hungary; Department of Genetics, Cell, and Immunobiology, Semmelweis University, Budapest, Hungary.
Tara L SpiveyInfectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA; Clinical Research Training Program (CRTP), National Institutes of Health, Bethesda, Maryland, USA; Department of General Surgery, Rush University Medical Center, Chicago, Illinois, USA.
Hui LiuInfectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Michele SommarivaInfectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA; Department of Biomedical Sciences for Health, Universita' degli Studi di Milano, Milan, Italy.
Jinguo ChenInfectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
John R WunderlichSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Giulia ParisiCancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Aviano, Italy.
Sara TomeiDepartment of Genetic Medicine, Weill Cornell Medical College in Qatar, Education City, Doha, Qatar.
Ben D AyotteDepartment of Biology, Northern Michigan University, Marquette, Michigan, USA.
David F StroncekCell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Joel A MalekDepartment of Genetic Medicine, Weill Cornell Medical College in Qatar, Education City, Doha, Qatar.
Paul F RobbinsSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Licia RivoltiniFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Michele MaioCancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Aviano, Italy.
Lotfi ChouchaneWeill Cornell Medical College in Qatar, Education City, Doha, Qatar.
Ena WangInfectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Francesco M MarincolaInfectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA; Research Branch, Sidra Medical and Research Centre, Doha, Qatar. Electronic address: fmarincola@sidra.org.

Funding

DNA Sequencing and FACS Core FacilitiesZICBC010948 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROBBINS, PAUL · 2009 to 2025
$35.6M
Surgery Branch Cell Prep CoreZICBC010905 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HALAS, HYUNMI · 2009 to 2025
$23.9M
Immunogenetic Study of Infectious Diseases and CancerZIACL002118 · CLC · CLINICAL CENTER · PI MARINCOLA, FRANCESCO M · 2009 to 2012
$0k
Develop novel assays for assessing cellular and gene therapiesZIACL002119 · CLC · CLINICAL CENTER · PI STRONCEK, DAVID · 2010 to 2025
$0k
Intramural NIH HHS Z99 CL999999Intramural NIH HHS ZIA CL002118
6 · The paper itself

Abstract

Recurrent metastatic melanoma provides a unique opportunity to analyze disease evolution in metastatic cancer. Here, we followed up eight patients with an unusually prolonged history of metastatic melanoma, who developed a total of 26 recurrences over several years. Cell lines derived from each metastasis were analyzed by comparative genomic hybridization and global transcript analysis. We observed that conserved, patient-specific characteristics remain stable in recurrent metastatic melanoma even after years and several recurrences. Differences among individual patients exceeded within-patient lesion variability, both at the DNA copy number (P<0.001) and RNA gene expression level (P<0.001). Conserved patient-specific traits included expression of several cancer/testis antigens and the c-kit proto-oncogene throughout multiple recurrences. Interestingly, subsequent recurrences of different patients did not display consistent or convergent changes toward a more aggressive disease phenotype. Finally, sequential recurrences of the same patient did not descend progressively from each other, as irreversible mutations such as homozygous deletions were frequently not inherited from previous metastases. This study suggests that the late evolution of metastatic melanoma, which markedly turns an indolent disease into a lethal phase, is prone to preserve case-specific traits over multiple recurrences and occurs through a series of random events that do not follow a consistent stepwise process.

Indexed as

TranscriptomeCell Line, TumorComparative Genomic HybridizationDisease ProgressionDNA Copy Number VariationsGene DeletionGene Expression Regulation, NeoplasticGenomicsHumansLongitudinal StudiesMelanomaNeoplasm Recurrence, LocalProto-Oncogene MasSkin NeoplasmsProto-Oncogene Mas

Identifiers

PMID24270663
PMCPMC3989423

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.